Live price temporarily unavailable.
Bio-Rad Laboratories (BIO) is a Health Care company in the Russell 1000. Latest news and coverage below.
Bio-Rad Laboratories revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $2.07B | $2.16B | $2.29B | $2.31B | $2.55B | $2.92B | $2.80B | $2.67B | $2.57B | $2.58B |
| Growth (year over year) | +2.4% | +4.4% | +6.0% | +1.0% | +10.1% | +14.8% | −4.1% | −4.7% | −3.9% | +0.7% |
| Gross profit | $1.14B | $1.19B | $1.22B | $1.26B | $1.44B | $1.64B | $1.57B | $1.43B | $1.38B | $1.34B |
| Gross margin | 55.0% | 55.0% | 53.4% | 54.4% | 56.5% | 56.1% | 55.9% | 53.4% | 53.7% | 51.9% |
| Operating income | $55.7M | $119.3M | −$103.3M | $229.7M | $421.3M | $500.3M | $482.6M | $337.8M | $269.0M | $47.2M |
| Operating margin | 2.7% | 5.5% | −4.5% | 9.9% | 16.6% | 17.1% | 17.2% | 12.6% | 10.5% | 1.8% |
| Net income | $26.0M | $122.2M | $365.6M | $1.76B | $3.81B | $4.25B | −$3.63B | −$637.3M | −$1.84B | $759.9M |
| Net margin | 1.3% | 5.7% | 16.0% | 76.1% | 149.8% | 145.6% | −129.5% | −23.9% | −71.9% | 29.4% |
| EPS (diluted) | $0.88 | $4.07 | $12.10 | $58.27 | $126.47 | $140.83 | −$121.79 | −$21.82 | −$65.36 | $27.85 |
| Balance sheet | ||||||||||
| Cash and equivalents | $456.3M | $383.8M | $431.5M | $660.7M | $662.2M | $470.8M | $434.2M | $403.8M | $488.1M | $529.8M |
| Total assets | $3.85B | $4.27B | $5.61B | $8.01B | $13.0B | $17.8B | $13.5B | $12.3B | $9.36B | $10.6B |
| Total liabilities | $1.27B | $1.34B | $1.59B | $2.25B | $3.09B | $4.11B | $3.89B | $3.56B | $2.79B | $3.12B |
| Long-term debt | $434.2M | $434.6M | $438.9M | $13.6M | $12.3M | $10.5M | $1.20B | $1.20B | $1.20B | $1.20B |
| Shareholders' equity | $2.58B | $2.93B | $4.02B | $5.76B | $9.89B | $13.7B | $9.62B | $8.74B | $6.57B | $7.45B |
| Cash flow | ||||||||||
| Operating cash flow | $216.1M | $104.1M | $285.5M | $457.9M | $585.0M | $669.5M | $194.4M | $374.9M | $455.2M | $532.2M |
| Capital expenditure | $141.4M | $111.3M | $129.8M | $98.5M | $108.6M | $133.7M | $112.8M | $156.7M | $165.6M | $157.6M |
| Free cash flow | $74.6M | −$7.20M | $155.7M | $359.4M | $476.4M | $535.7M | $81.6M | $218.2M | $289.6M | $374.6M |
| Share buybacks | $0 | $2.92M | $48.9M | $28.0M | $100.0M | $50.0M | $215.7M | $428.7M | $203.6M | $295.5M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $649.7M | $667.5M | $585.4M | $651.6M | $653.0M | $693.2M | $592.1M | $651.0M |
| Growth (year over year) | +2.8% | −2.0% | −4.2% | +2.1% | +0.5% | +3.9% | +1.1% | −0.1% |
| Gross profit | $355.9M | $342.0M | $306.0M | $345.3M | $343.4M | $345.2M | $309.4M | $345.8M |
| Gross margin | 54.8% | 51.2% | 52.3% | 53.0% | 52.6% | 49.8% | 52.3% | 53.1% |
| Operating income | $64.5M | $58.4M | $23.7M | $77.1M | $65.3M | −$118.9M | $34.1M | $72.6M |
| Operating margin | 9.9% | 8.7% | 4.0% | 11.8% | 10.0% | −17.2% | 5.8% | 11.2% |
| Net income | $653.2M | −$715.8M | $64.0M | $317.8M | −$341.9M | $720.0M | −$527.1M | $371.4M |
| Net margin | 100.5% | −107.2% | 10.9% | 48.8% | −52.4% | 103.9% | −89.0% | 57.1% |
| EPS (diluted) | $23.34 | −$25.89 | $2.29 | $11.67 | −$12.70 | $26.59 | −$19.55 | $13.85 |
| Balance sheet | ||||||||
| Cash and equivalents | $410.4M | $488.1M | $521.4M | $369.3M | $395.8M | $529.8M | $507.2M | $517.0M |
| Total assets | $10.6B | $9.36B | $9.53B | $10.2B | $9.70B | $10.6B | $9.79B | $10.3B |
| Total liabilities | $3.12B | $2.79B | $2.85B | $3.09B | $2.96B | $3.12B | $2.94B | $3.08B |
| Long-term debt | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $1.20B | $802.9M | $803.0M |
| Shareholders' equity | $7.49B | $6.57B | $6.68B | $7.13B | $6.74B | $7.45B | $6.85B | $7.17B |
| Cash flow | ||||||||
| Operating cash flow | $163.6M | $124.2M | $129.9M | $116.5M | $120.9M | $164.9M | $108.1M | $98.7M |
| Capital expenditure | $40.2M | $42.9M | $34.4M | $45.7M | $31.7M | $45.8M | $30.0M | $32.0M |
| Free cash flow | $123.4M | $81.3M | $95.5M | $70.8M | $89.2M | $119.1M | $78.1M | $66.7M |
| Share buybacks | $97.9M | $0 | $101.9M | $140.2M | $53.4M | $0 | $47.8M | $31.5M |
From Bio-Rad Laboratories's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide.
Source: Wikipedia — Bio-Rad Laboratories
- Headquarters
- Hercules, California From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International